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Abstract
The RNA guanylyltransferase (GTase) is involved in the synthesis of the
m7Gppp-RNA cap structure found at the 59 end of
eukaryotic mRNAs. GTases are members of the covalent nucleotidyl transferase superfamily, which also includes DNA and
RNA ligases. GTases catalyze a two-step reaction in which they initially utilize GTP as a substrate to form a covalent enzyme-
GMP intermediate. The GMP moiety is then transferred to the diphosphate end of the RNA transcript in the second step of
the reaction to form the Gppp-RNA structure. In the current study, we used a combination of virtual database screening,
homology modeling, and biochemical assays to search for novel GTase inhibitors. Using this approach, we demonstrate that
mycophenolic acid (MPA) can inhibit the GTase reaction by preventing the catalytic transfer of the GMP moiety onto an
acceptor RNA. As such, MPA represents a novel type of inhibitor against RNA guanylyltransferases that inhibits the second
step of the catalytic reaction. Moreover, we show that the addition of MPA to S. cerevisiae cells leads to a reduction of
capped mRNAs. Finally, biochemical assays also demonstrate that MPA can inhibit DNA ligases through inhibition of the
second step of the reaction. The biological implications of these findings for the MPA-mediated inhibition of members of
the covalent nucleotidyl superfamily are discussed.
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Introduction
The synthesis and maturation of eukaryotic mRNAs are crucial
events for gene expression. During mRNA synthesis, eukaryotic
mRNAs undergo a series of essential modifications before being
exported to the cytoplasm where they are translated into proteins
[1]. These processing events include the addition of a cap structure
at the 59 terminus, the splicing out of introns, the editing of specific
nucleotides, and the acquisition of a poly(A) tail at the 39 terminus.
The RNA cap structure found at the 59 end of mRNAs is critical
for the splicing of the cap-proximal intron, the transport of
mRNAs from the nucleus to the cytoplasm, and for both the
stability and translation of mRNAs [2,3]. The cap is synthesized
by a series of three enzymatic reactions [4]. The first step involves
the hydrolysis of the RNA 59-triphosphate end of the nascent RNA
by an RNA triphosphatase to form a diphosphate end. An RNA
guanylyltransferase then catalyzes a two-step reaction in which it
initially utilizes GTP as a substrate to form a covalent enzyme-
GMP intermediate. The GMP moiety is then transferred to the
diphosphate end of the RNA transcript in the second step of the
reaction to form the GpppN structure. The guanosine residue is
finally methylated by an RNA (guanine-N7)-methyltransferase to
form the typical
m7GpppN cap structure.
A number of different microbial pathogens code for their own
enzymes involved in the synthesis of a cap structure [5,6,7,8,9,10].
Although the RNA cap structures originating from human and
microbial enzymes are often identical, the physical organization of
the genes, subunit composition, structure and catalytic mecha-
nisms of the microbial-encoded enzymes involved in the synthesis
of the RNA cap structure are often significantly different from
those of host cells [2]. As a consequence these pathogenic cap-
forming enzymes are potential targets for anti-microbial drugs.
During the past few years, both the RNA triphosphatase and the
RNA (guanine-N7) methyltransferase (N7-MTase) components of the
RNA capping machinery have been major targets for the development
of drugs directed against RNA cap synthesis [11,12,13,14,15,
16,17,18,19,20]. Of all the enzymes involved in RNA capping, the
RNA guanylyltransferase (GTase) has traditionally been considered a
poor candidate as an anti-microbial target because of the high
mechanistic and structural conservation of this enzyme across species
[21]. Based on various crystal structures of GTases, a general
mechanism for phosphoryltransfer has previously been elucidated
which involves conformational changes between an open and closed
form of the enzyme [22,23]. In the first step of the reaction, GTP binds
to the open form of the enzyme which promotes closure of the N-
terminal nucleotidyl transferase (NT) domain and the C-terminal
oligomer-binding (OB) fold domain. This closure is stabilized by
interactions between the residues of the NT domain, the bound
nucleotide, and residues on the OB fold domain. Domain closure is
then followed by hydrolysis of the GTP substrate to produce the
enzyme-GMP covalent intermediate. Hydrolysis of GTP disrupts the
interactions between the bound guanylate and the C-terminal OB fold
domain, thus destabilizing the closed form of the enzyme, which opens
up with the concomitant release of pyrophosphate. This exposes the
RNA-binding site of the enzyme, thereby allowing the subsequent
transfer of the GMP moiety onto the acceptor RNA. Figure 1
summarizes the mechanistic and structural pathway used by GTases.
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inhibitor of the GTase reaction [24]. Its mechanism of action is
purported to occur through substrate binding inhibition on account
of its analogous nature to pyrophosphate (PPi), a product of the
GTase reaction. Ribavirin, a broad-spectrum nucleoside analogue
approved for the treatment of various viral infections, is another
inhibitor of the GTase activity [25]. Biochemical studies have shown
that ribavirin triphosphate can actually be used as a substrate by the
vaccinia virus GTase to form a covalent enzyme-ribavirin mono-
phosphate intermediate reminiscent of the covalent enzyme-GMP
intermediate [25]. Furthermore, ribavirin monophosphate can be
transferred to the diphosphate end of an RNA transcript to form the
unusual RpppN structure [25]. However, RNA transcripts blocked
with ribavirin are not recognized efficiently by the cap-binding
protein eIF4E, and are not translated into proteins [26]. The use of
guanine-N7 methylation-inert cap donor molecules could potentially
prove to be an interesting line of research for the development of anti-
microbial drugs. However, on account of the possibility of off-targets,
the risk of major side effects upon tratment with GTase substrate/
product analogs remains. Several issues related to the specificity
problem faced with these inhibitors can likely be partially resolved by
the development of non-nucleoside inhibitors.
In the current study, we used a combination of virtual database
screening, homology modeling, and biochemical assays to search
for novel GTase inhibitors. We demonstrate that mycophenolic
acid, a compound which is currently used both in cancer and
immunosuppressive chemotherapy, is an inhibitor of the GTase
reaction. The biological implications of these findings for the
MPA-mediated inhibition of RNA capping are discussed.
Materials and Methods
Structure-based virtual screening
To identify potential candidate compounds that can bind to
GTases, the crystal structures of various GTases were retrieved
from the Protein Data Bank (Chlorella virus: 1CKN and 1CKO;
Candida albicans: 1P16; S. cerevisiae: 3KYH). The chemical databases
used in our virtual screening included the Sigma-Aldrich,
Ambinter, ASINEX, IS Chemical technology, MolPort, and Vitas
M Laboratory catalogs. Collectively, these 6 databases offered a
collection of 13,800,000 small-molecule compounds.
The molecular docking program DOCK (Version 4.0) was used
to perform the virtual screening [27]. Componds displaying at least
80% of structural similarity to GTP or ATP (.25,000 compounds)
were screened for the binding to the four GTases. The levels
of similarities were measured using the Tanimoto equation [28]
and the PubChem dictionary-based binary fingerprint (http://
pubchem.ncbi.nlm.nih.gov/). Based on the binding models of these
compounds predicted by DOCK, the X-SCORE program (Version
1.1) was applied to obtain an estimate of the binding affinities of
these compounds [29]. The compounds were then ranked
according to their binding affinities as estimated by X-SCORE.
Expression and purification of proteins
The RNA guanylyltransferases from S. cerevisiae (Ceg1), vaccinia
virus (D1R), Chlorella virus (A103R), and human (HCE) were
expressed and purified as described before [24,25,30,31]. The
ATP-dependent ligase DNA ligase from Chlorella virus (ChVLig)
was also expressed and purified as described previously [32].
Assay for enzyme-GMP complex formation
The assay was performed by incubating the enzyme (0.1 mM)
with 10 mM[ a-
32P]GTP in a buffer containing 50 mM Tris-HCl,
pH 8, 5 mM DTT, and 5 mM MgCl2 for 5 min at 30uC. The
reactions were stopped by the addition of EDTA to 10 mM and
SDS to 1%. The reactions were analyzed by electrophoresis
through a 12.5% polyacrylamide gel containing 0.1% SDS. The
radiolabeled proteins were visualized by autoradiography of the
gel. The extent of covalent complex formation was quantitated by
scanning the gel with a PhosphorImager (Amersham Biosciences).
Preparation of RNA substrates
An RNA substrate of 81 nucleotides was synthesized with the
MAXIscript kit (Ambion) using T7 RNA polymerase. The RNA
Figure 1. Structural and mechanistic pathway used by RNA guanylyltransferases. The mechanism for phosphoryltransfer involves
conformational changes between an open and closed form of the enzyme [22,23]. GTP (grey sphere) initially binds to the apo-enzyme (structure 1)
which promotes closure of the N-terminal nucleotidyl transferase (NT) domain and the C-terminal oligomer-binding (OB) fold domain (structure 3).
This is followed by hydrolysis of the GTP substrate to produce the enzyme-GMP covalent intermediate (structure 4). Hydrolysis of GTP disrupts the
interactions between the bound guanylate and the C-terminal OB fold domain, thus destabilizing the closed form of the enzyme, which opens up
with the concomitant release of pyrophosphate (structure 5). This exposes the RNA-binding site of the enzyme (exact location unknown), thereby
allowing the subsequent transfer of the GMP moiety onto the acceptor RNA (structure 7). The capped RNA is then released and the enzyme can
reinitiate the pathway.
doi:10.1371/journal.pone.0024806.g001
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gene) that had been linearized with HindIII. The RNA substrate
was purified on a denaturing 20% polyacrylamide gel and
visualized by ultraviolet shadowing. The corresponding band
was excised and then eluted from the gel by an overnight
incubation in 0.1% SDS and 0.5 M ammonium acetate. The
RNA was then precipitated with ethanol and quantitated by
spectrophotometry. Alternatively, radiolabeled RNA substrates
were also synthesized by adding [a-
32P]ATP or [a-
32P]GTP to the
transcription reaction.
The purified 59-triphosphorylated RNA was further processed
to obtain a diphosphorylated 59 end using the S. cerevisiae RNA 59-
triphosphatase (Cet1) which was expressed and purified as
described before [33]. The diphosphorylated RNA (ppRNA) was
precipitated with ethanol, resuspended, quantitated by spectro-
photometry, and stored at 220uC.
Molecular docking
Docking calculations were carried out using the Docking Server
software and the Dreiding force field was used for energy
minimization of MPA using built-in Chemaxon tools in Docking
Server [34]. PM6 semi-empirical charges calculated by MO-
PAC2007 were added to the ligand atoms. Non-polar hydrogen
atoms were merged and rotatable bonds were defined [35].
Docking calculations were carried out using the Chlorella virus and
Candida albicans RNA guanylyltransferase crystal structures (Protein
Data Bank 1CKN and 1P16). Essential hydrogen atoms, Kollman
united atom type charges and solvation parameters were added
with the aid of AutoDock tools [36]. Affinity (grid) maps of
20620620 A ˚ grid points and 0.375 A ˚ spacing were generated
using the Autogrid program [36]. AutoDock parameter set- and
distance-dependent dielectric functions were used in the calcula-
tion of the van der Waals and the electrostatic terms, respectively.
Docking simulations were performed using the Lamarckian
genetic algorithm and the Solis and Wets local search method
[37]. Initial position, orientation, and torsions of the ligand
molecules were set randomly. Each docking experiment was
derived from two different runs that were set to terminate after a
maximum of 2,500,000 energy evaluations. The population size
was set to 150. During the search, a translational step of 0.2 A ˚,
and quaternion and torsion steps of 5 A ˚ were applied.
UV-crosslinking experiments
UV-crosslinking between the internally
32P-labeled RNA of
81 nt and the yeast GTase was performed in a crosslink buffer
(50 mM Tris pH 7.5, 5 mM DTT, 5 mM MgCl2). The protein
(12 mM) was incubated with GTP (1 mM) and different concen-
trations of MPA for 10 minutes at 30uC. The radiolabeled RNA
(3 mM) was added to the reaction mixture and incubated for
5 minutes at 30uC. The reaction mixture was exposed to UV light
(254 nm, 20 Joules/cm
2) for 5 min at 30uC using a Stratalinker
2400 UV Crosslinker (Stratagene). The crosslink mixture was
denatured (50 mM Tris-HCl, pH 7.0, 5% sucrose, 5% b-
mercaptoethanol, 2% SDS) and separated by electrophoresis on
a 12% SDS-PAGE. The gel was analyzed by phosphorimaging.
Ligation assay
The ligation reaction was performed as described previously
[32]. Briefly, a 36 bp DNA duplex harboring a centrally placed
nick was used as a substrate. The 18-mer constituting the 59-
phosphate-terminated strand 59-d(ATTCCGATAGTGACTA-
CA)-39 was 59-radiolabeled and gel purified as described before.
This labeled 18-mer was then annealed to a complementary 36-
mer in the presence of a 39-OH 18-mer strand 59-d(CAT-
ATCCGTGTCGCCCTT)-39 [38,39]. Ligation reaction mixtures
containing 50 mM Tris-HCl (pH 7.5), 5 mM DTT, 10 mM
MgCl2, 1 mM ATP, nicked duplex substrate and the Chlorella virus
DNA ligase were incubated at 22uC for 15 min. The reactions
were stopped by the addition of 1 ml 0.5 M EDTA and 5 ml
formamide. The samples were heated at 95uC for 5 min and then
analyzed by electrophoresis through a 17% polyacrylamide gel
containing 7 M urea. The extent of ligation was determined by
scanning the gel with a PhosphorImager (Amersham Biosciences).
Primer extension analysis of 59 ends
Primer extension reactions were performed as described
previously [40] using a 59
32P-labeled 18-mer DNA oligonucleo-
tide complementary to the 59 region of the SSA1 mRNA (positions
+1t o+19). Total RNA was extracted form S. cerevisiae cells that
were grown in the presence or absence of 500 mg/ml MPA for 3 h
at 30uC. The primer extension reactions were analyzed by
electrophoresis through a 8% polyacrylamide gel containing 7 M
urea in TBE and visualized by autoradiography.
Results and Discussion
Identification of mycophenolic acid through virtual
database screening
We initially performed a virtual screen of more than 25,000
purine-related compounds for their ability to bind to the GTases of
Chlorella virus (open and closed forms), S. cerevisiae (open form), and C.
albicans (open form). The ligands were docked and ranked according
to their respective docking scores. Our initial screen indicated that
very few compounds bound to the open forms of these three different
GTases. In all cases, the highest scoring compounds were not
predicted to bind with very strong affinities to the enzymes (predicted
Kd.2 mM). However, one compound (mycophenolic acid) docked
efficiently in the cavity of the closed form of the Chlorella virus GTase
(predicted Kd of 280 mM). Mycophenolic acid (MPA, Fig. 2A) is a
well-known inhibitor of inosine monophosphate dehydrogenase
(IMPDH), a key cellular enzyme required for biosynthesis of guanine
nucleotides [41]. Because T- and B-lymphocytes are critically
dependent for their proliferation on de novo synthesis of purines,
whereas other cell types can utilize salvage pathways, IMPDH
inhibitors have potent cytostatic effects on lymphocytes [42,43].
Accordingly, MPA has been used both in cancer and immunosup-
pressive chemotherapy as wll as in antiviral and antifungal therapy
[44,45,46,47,48,49,50,51,52]. Because GTP is required for the
transcription and replication of cellular and microbial genomes, it
has traditionally been assumed that the decrease in the cytosolic
concentration of GTP could affect both cell growth and the
multiplication of fungal and viral pathogens.
MPA inhibits the RNA guanylyltransferase activity
The ability of MPA to inhibit the GTase of the model organism
S. cerevisiae (Ceg1 protein) was then investigated. The GTase
activity is actually a two-step ping-pong reaction in which the
enzyme first reacts with GTP to produce the enzyme–GMP (EpG)
covalent intermediate with the concomitant release of pyrophos-
phate [2]. In the second step of the reaction, the GMP moiety is
then transferred to a 59-diphosphate RNA. The ability of MPA to
inhibit the complete GTase reaction (both steps) was monitored
using a standard GTase assay in which the purified enzyme was
incubated with [alpha-
32P]GTP and a 59-diphosphate acceptor
RNA. The reaction products were then analyzed on a denaturing
polyacrylamide gel. As can be seen in figure 2B, the presence of
increasing concentrations of MPA significanlty decreased the
transfer of the radiolabeled GMP moiety onto the acceptor RNA.
Mycophenolic Acid Is an RNA Capping Inhibitor
PLoS ONE | www.plosone.org 3 September 2011 | Volume 6 | Issue 9 | e24806Figure 2. Mycophenolic acid inhibits the RNA guanylyltransferase activity. (A) Molecular structure of mycophenolic acid (MPA). (B)
Increasing concentrations of MPA inhibit the complete RNA guanylyltransferase reaction. A standard GTase assay in which the purified enzyme (1 mM)
was incubated with both [alpha-
32P]GTP and a 59-diphosphate acceptor RNA was performed in the presence of increasing concentrations of MPA.
The reaction products were analyzed on a denaturing polyacrylamide gel and quantified (right side of the panel). (C) MPA is not a potent inhibitor of
the first step of the GTase reaction. The formation of the enzyme-GMP covalent intermediate was monitored by incubating the purified enzyme
(1 mM) in the presence of [alpha-
32P]GTP and increasing concentrations of MPA. The radiolabeled covalent enzyme-GMP complex was then visualized
by autoradiography following electrophoresis on a denaturing 12.5% polyacrylamide gel. The radiolabeled enzyme-GMP complex was quantified by
phosphorimaging (right side of the panel). (D) The second step of the GTase reaction is inhibited by MPA. The transfer of the GMP moiety onto an
acceptor RNA was evaluated by pre-incubating the enzyme (1 mM) with [alpha-
32P]GTP (10 mM) to ensure formation of the radiolabeled covalent
enzyme-GMP complex, followed by the addition of the acceptor 59-diphosphate RNA (3 mM) in the presence of MPA. Formation of the radiolabeled
capped GpppRNA was monitored following electrophoresis on a denaturant polyacrylamide gel. The radiolabeled GpppRNA was then quantified by
phosphorimaging (right side of the panel).
doi:10.1371/journal.pone.0024806.g002
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360 mM, and by 80% at 900 mM.
In order to characterize the inhibition of the GTase activity by
MPA, we next set out to investigate which of the two catalytic steps
of the reaction is inhibited by MPA. The first step of the reaction,
i.e. the formation of the enzyme-GMP covalent intermediate, was
monitored by incubating the purified enzyme in the presence of
[alpha-
32P]GTP. The radiolabeled covalent enzyme-GMP com-
plex was then visualized by autoradiography following electro-
phoresis on a denaturant polyacrylamide gel. Our results indicate
that very high concentrations of MPA are required to inhibit the
formation of the enzyme-GMP covalent complex (Fig. 2C). We
determined that a concentration of 3 mM of MPA is required to
inhibit the first step of the reaction by 50%, a concentration that
corresponds to 8-times the amount required to inhibit the overall
GTase reaction (both steps). The effect of MPA on the second step
of the RNA reaction (i.e. the transfer of the GMP moiety onto an
acceptor RNA) was next evaluated by pre-incubating the enzyme
with GTP to ensure formation of the covalent enzyme-GMP
complex, followed by the addition of the acceptor 59-diphosphate
RNA in the presence of MPA. Using such an approach, it was
determined that a concentration of 640 mM of MPA is sufficient to
inhibit 50% of the second step of the GTase reaction (Fig. 2D).
Taken together, these results indicate that MPA inhibits the
GTase reaction mainly through inhibition of the catalytic transfer
of the GMP moiety onto an acceptor RNA.
MPA is not a substrate for the RNA guanylyltransferase
In the typical GTase reaction, the nucleophilic attack on the a-
phosphate of GTP by the enzyme during the first step of the
reaction results in the formation of a covalent intermediate in which
GMP is linked via a phosphoamide bond to a lysine residue of the
enzyme [2]. Interestingly, it has previously been demonstrated that
the nucleotide analog ribavirin triphosphate can be used as a
substrate by the GTase to form an enzyme-RMP covalent
intermediate [25]. Although MPA is not a nucleoside analog per
se, we were still interested to monitor its ability to potentially be used
as a substrate by the enzyme. The appearance of a slower migrating
protein species is traditionally observed upon electrophoresis
through a polyacrylamide gel when an RNA capping enzyme is
incubated with GTP [25]. This slower migrating species corre-
sponds to the enzyme with covalently bound GMP. We therefore
incubated the enzyme in the presence of GTP or MPA and the
polypeptide was analyzed by capillary electrophoresis. The
appearance of a slower migrating protein species was observed
repeatedly when the protein was incubated with GTP (Fig. 3A).
However, this was not observed when the enzyme was incubated
with MPA (Fig. 3A). We therefore conclude that MPA is not a
substrate for the GTase. Accordingly, the transfer of MPA to an
acceptor RNA could not be detected when the enzyme was
incubated in the presence of MPA (Fig. 3B). This was tested by
incubatingtheenzyme withan RNAsubstrate(81 nt) synthesizedin
the presence of [alpha-
32P]GTP. This RNA substrate harbored a
radiolabelled diphosphate 59-end (59 ppG-RNA 39, where the
boldface indicates the radiolabelled moiety) and 27 internally
labelled guanosine residues. The RNA was then incubated with the
GTase in the presence of GTP or MPA. The products of the
reaction were extracted with phenol/chloroform and the RNA
acceptor molecules were recovered by ethanol precipitation.
Aliquots of the RNA samples were then digested with nuclease P1
Figure 3. MPA is not a substrate for the RNA guanylyltransferase. (A) Capillary electrophoresis analysis of the RNA capping reaction. The
GTase reactions were performed in the presence of the purified enzyme (1 mM) and GTP (1 mM) or MPA (1 mM), and the reaction products were
analyzed by capillary electrophoresis. An untreated protein was also used as a control (-). The positions and sizes (in kDa) of the size markers (M) are
indicated on the left. Masses are shown above the corresponding bands. (B) RNA capping reaction. The reaction mixtures contained 1 mg of purified
enzyme, 23 pmol of radiolabelled 59 diphosphate-terminated RNA (59 ppG-RNA 39, where the boldface indicates the radiolabelled moiety), and either
1 mM GTP or 1 mM MPA. An untreated control was also used in these assays (Ø). The reactions were incubated at 30uC for 30 min, and
unincorporated nucleotides were removed by multiple rounds of ethanol precipitation. The RNAs were extracted with phenol/chloroform and
recovered by ethanol precipitation. Aliquots of the RNA samples were adjusted to 50 mm NaOAc, pH 5.2, and digested with nuclease P1 (5 mg) for
60 min at 37uC. The reaction was then adjusted to 50 mm Tris-HCl, pH 8.0, and digested with alkaline phosphatase (1 unit) for 60 min at 37uC
(P1+AP). The reaction products were analyzed by thin layer chromatography on a polyethyleneimine-cellulose plate developed with 0.5 M LiCl and
1 M formic acid. An autoradiogram of the plate is shown. The positions of the chromatographic origin (ori), inorganic phosphate (Pi), and GpppG are
indicated.
doi:10.1371/journal.pone.0024806.g003
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PLoS ONE | www.plosone.org 5 September 2011 | Volume 6 | Issue 9 | e24806Figure 4. Molecular docking model for the binding of MPA to the closed form of the Chlorella virus GTase bound to GMP. (A) Ribbon
diagram of the open form of the enzyme (PDB: 1CKO). The positions of the N-terminal nucleotidyl transferase (NT) and the C-terminal oligomer-
binding (OB) fold domains are indicated. (B) Ribbon diagrams looking at the interaction of MPA with the GTase (PDB: 1CKN) bound to GMP. (C) Close-
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cellulose thin layer chromatography (Fig. 3B). The transfer of
radiolabeled GMP to RNA was confirmed by demonstrating the
release of a GpppG structure following digestion of the RNA
samples with both nuclease P1 and alkaline phosphatase. However,
the transfer of MPA to the acceptor RNA could not be detected
when the enzyme was incubated in the presence of MPA (Fig. 3B).
Overall, these results demonstrate that MPA is not a substrate for
the GTase, and that it cannot be transferred to an acceptor RNA.
Mechanistic/Structural implications
In order to better understand the mechanism by which MPA
inhibits the transfer of GMP to RNA, we set out to use the power
of molecular docking to provide information on the interaction
between MPA and both the open and closed conformers of the
RNA guanylyltransferase (Fig. 4A and B). Using extensive
computational docking and structure optimizations, we generated
models of MPA bound to the closed form enzyme–GMP complex
of the Chlorella virus GTase. More than 2,000,000 energy
evaluations were performed in order to provide an accurate
description of the interactions. The models underwent 150 rounds
of steepest descent energy minimization and did not contain
energetically unfavorable bonds, angles or torsions.
Analysis of the molecular docking model predicts that MPA
binds in the cleft created by the closure of the N-terminal and C-
terminal domains. The space-filling model suggests that the
molecular structure of MPA is sterically complementary to the
cleft between the domains (Fig. 4B). The molecular docking model
provides instructive findings on the interaction between specific
residues of the enzyme and MPA (Fig. 4B). Arg106 and Asp213 of
the N-terminal NT domain and Lys234, Asp244, Gln293, Arg295,
Asp297, and Glu281 of the C-terminal OB fold domain would be
involved in the coordination of the MPA through hydrogen-
bonding (Fig. 4C). Ile86 (N-terminal) is predicted to make a
hydrophobic interaction with MPA, which is located 4.0 A ˚ away
from the bound GMP (Fig. 4D).
As observed in our initial virtual screening, the molecular
docking analyses suggest that MPA only binds to the closed form
of the enzyme. No significant binding of MPA was detected when
the molecular docking experiments were performed on the open
forms of the C. albicans, S. cerevisiae and Chlorella virus RNA
guanylyltransferases bound with GMP. It is tempting to speculate
that the opening of the active site of the enzyme that is normally
observed following the hydrolysis of GTP to produce the enzyme-
GMP covalent intermediate [23] is inhibited by MPA. Following
the formation of the GMP adduct, the enzyme must open up to
provide access for the incoming mRNA substrate, since this site is
blocked off in the closed form of the enzyme [23]. The presence of
multiple interactions between MPA and residues of both the N-
terminal and C-terminal domains of the enzyme likely inhibits this
critical conformational change that is required for the binding of
RNA. In order to validate this hypothesis, cross-linking assays were
used to monitor the binding of radiolabelled RNA to the enzyme-
GMP complex with or without MPA. An RNA harboring a 59-
triphosphate end was used as a ligand instead of the classical RNA
with a 59-diphosphate since the latter would lead to the transfer of
the GMP moiety onto the RNA. Using this approach, an apparent
Kd of 30 mM could be estimated for the binding of the RNA to the
enzyme-GMP complex (data not shown). However, the binding of
RNA to the enzyme-GMP/MPA complex was severely decreased
in the presence of MPA (Fig. 5A). An IC50 value of 410 mM could
be estimated from the inhibition assays (Fig. 5B). These results
demonstrate that the presence of MPA inhibits the binding of the
enzyme-GMP complex to RNA.
Specificity
GTases are members of the RNA/DNA nucleotidyltransferase
superfamily that share six conserved sequence motifs (Fig. 6A) and
a similar three-dimensional architecture consisting of an N-
terminal NT domain and a C-terminal OB fold domain [21]. As
observed previously, the NT domain (aa 1–243) of the C. albicans
GTase aligns to the Chlorella virus GTase enzyme with 1.9 A ˚ rmsd
over 210 amino acids (26% side chain identity) [53]. In addition,
the C. albicans GTase OB domain (aa 244–390) aligns to the
Chlorella virus GTase OB domain with 1.8 A ˚ rmsd over 72 amino
acids (28% identity) [53]. Because of the high level of structural
Figure 5. Binding of MPA to the enzyme-GMP complex inhibits the interaction with RNA. (A) The enzyme-GMP complex was incubated
with a radiolabeled RNA substrate (3 mM) of 81 nucleotides in the presence of increasing concentrations of MPA. UV-cross-linking assays were
performed to monitor the binding of radiolabelled RNA to the enzyme-GMP complex and visualized by SDS-PAGE analysis and autoradiography. (B)
The reaction products were quantified by phosphorimaging.
doi:10.1371/journal.pone.0024806.g005
up view of the MPA binding pocket with emphasis on the residues interacting with MPA. (D) The side chains of of amino acids that are predicted to
interact with MPA are shown, and the distances are indicated (in Angstro ¨ms).
doi:10.1371/journal.pone.0024806.g004
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hypothesized that MPA should inhibit the GTases of various
organisms. We therefore expressed and purified the RNA
guanylyltransferases from vaccinia virus and Chlorella virus, as well
as the corresponding human enzyme. Our results demonstrate that
MPA inhibits all these GTases to the same extent than the S.
cerevisiae homolog (Fig. 6C). IC50 values similar to the ones
obtained for both the first (,3 mM) and second step (,620 mM)
of the GTase reaction were observed when MPA was added to the
reactions catalyzed by the vaccinia, Chlorella, and human enzymes.
Overall, these results indicate that MPA inhibits the activity of
different GTases through a similar mechanism that mainly
prevents the catalytic transfer of the GMP moiety onto an
acceptor RNA.
Inhibition of DNA ligase
GTases are members of the covalent nucleotidyl transferase
superfamily, which also includes DNA and RNA ligases [21]. The
crystal structures of various family members revealed a common
tertiary structure consisting of an N-terminal NT domain and a C-
terminal OB-fold domain [22,23,53,54,55]. Based on both the
sequence and structural similarities between GTases and DNA/
RNA ligases (Fig. 6A and B), it is tempting to speculate that MPA
might also be an inhibitor of DNA/RNA ligases. DNA/RNA
ligation entails three sequential nucleotidyl transfer steps, and the
first two steps are mechanistically related to the GTase reaction
[56]. In the first step of the ligation reaction, nucleophilic attack on
the a-phosphorus of ATP by ligase results in the formation of a
covalent ligase-adenylate intermediate with the concomitant
release of pyrophosphate. In the second step, AMP is transferred
to the 59-end of the 59-phosphate-terminated DNA strand to form
a DNA-adenylate complex. In the last step of the reaction, The the
polynucleotides are joined with the concomitant release of AMP
[56]. To verify the potential ability of MPA to inhibit DNA/RNA
ligases, we have monitored the effect of MPA on the purified DNA
ligase encoded by Chlorella virus.
Figure 6. MPA inhibits the GTases of various origins. (A) Sequence conservation in members of the RNA/DNA nucleotidyltransferase
superfamily. Members of this family share six conserved motifs (I, III, IIIa, IV, V, VI). An amino acid alignment of the GTases from S. cerevisiae, C.
albicans, Chlorella virus, vaccinia virus, human, and the DNA ligase of Chlorella virus is presented. (B) Members of the RNA/DNA nucleotidyltransferase
superfamily harbor a similar three-dimensional architecture consisting of an N-terminal NT domain and a C-terminal OB fold domain. The structures of
the S. cerevisiae GTase (PDB: 3KYH), C. albicans GTase (PDB: 1P16), Chlorella virus GTase (PDB: 1CKN), and Chlorella virus DNA ligase (PDB: 1P8L) are
shown. (C) The effect of MPA on the first and second step of the GTase reaction was monitored on the GTases from S. cerevisiae, Chlorella virus,
vaccinia virus, and human. Both reactions were performed in the presence of increasing concentrations of MPA as described in the legend of figure 1.
doi:10.1371/journal.pone.0024806.g006
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PLoS ONE | www.plosone.org 8 September 2011 | Volume 6 | Issue 9 | e24806Figure 7. MPA inhibits the DNA ligase activity. (A) MPA inhibits the strand-joining activity of DNA ligase. Ligation reactions (50 mM Tris-HCl
pH 7.5, 5 mM DTT, 10 mM MgCl2, 1 mM ATP, 500 fmol 1-nt gap DNA substrate and 6 pmol of the Chlorella virus DNA ligase) were performed at 22uC
for 15 min in the presence of increasing concentrations of MPA. The samples were analyzed by electrophoresis through a 17% polyacrylamide gel
containing 7 M urea. An autoradiogram of the gel is shown. The positions of the input 59-monophosphate 18-mer strand (pDNA) and the 36-mer
ligation product are indicated. The radiolabeled ligated product was then quantified by phosphorimaging (right side of the panel). (B) High
concentrations of MPA are required to inhibit the first step of the ligase reaction. The formation of the enzyme-AMP covalent intermediate was
monitored by incubating the purified enzyme in the presence of [alpha-
32P]ATP and increasing concentrations of MPA. The radiolabeled covalent
enzyme-AMP complex was then visualized by autoradiography following electrophoresis on a denaturant polyacrylamide gel. The radiolabeled
enzyme-AMP complex was then quantified by phosphorimaging (right side of the panel). (C) The second step of the ligase reaction is inhibited by
MPA. The transfer of the AMP moiety onto a radiolabeled 59-monophosphate 18-mer strand (pDNA) was evaluated by pre-incubating the enzyme
with ATP to ensure formation of the radiolabeled covalent enzyme-AMP complex, followed by the addition of a 1-nt gapped substrate in the
presence of increasing concentrations of MPA. Conversion of the 59-
32P-labeled 18-mer strand into an adenylated species (AppDNA) was monitored
by electrophoresis on a denaturant polyacrylamide gel. Lane 1: reaction performed in the absence of protein (-). The formation of the radiolabeled
ApppDNA was quantified by phosphorimaging (right side of the panel).
doi:10.1371/journal.pone.0024806.g007
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monitored by incubating the purified enzyme with ATP and a
DNA duplex containing a centrally located nick. The reaction
products were then analyzed on a denaturing polyacrylamide gel.
As can be seen in Fig. 7A, the presence of increasing
concentrations of MPA significanlty decreased strand joining by
the Chlorella virus DNA ligase. MPA was shown to inhibit the
strand-joining activity by 50% at 700 mM. We next set out to
investigate which of the first two catalytic steps of the ligation
reaction is inhibited by MPA. The first step of the reaction, i.e. the
formation of the enzyme-AMP covalent intermediate, was
monitored by incubating the purified enzyme in the presence of
[alpha-
32P]ATP. The radiolabeled covalent enzyme-AMP com-
plex was then visualized by autoradiography following electro-
phoresis on a denaturant polyacrylamide gel. Similarly to what
was observed in the case of the GTase activity, our results indicate
that very high concentrations of MPA are required to inhibit the
first step of the reaction, i.e. the formation of the enzyme-AMP
covalent complex (Fig. 7B). We determined that a concentration of
,3.0 mM of MPA is required to inhibit the first step of the
ligation reaction by 50%, a concentration that corresponds to 4-
times the amount required to inhibit the overall reaction. The
effect of MPA on the second step of the ligation reaction (i.e. the
transfer of the AMP from ligase-adenylate to a 59-phosphate
terminus acceptor DNA) was next evaluated. In a typical ligation
reaction, the adenylate-DNA intermediate would not be detected
since the enzyme is highly efficient in ligating the two DNA strands
[57]. However, as reported previously [58], the adenylate-DNA
intermediate can accumulate to high levels when the enzyme acts
on a substrate that contains a 1-nt gap between the reactive 39-OH
and 59-phosphate strands. Using such an approach, the incubation
of the enzyme with ATP and a gapped DNA substrate resulted in
the conversion of the 59-radiolabeled 18-mer strand into an
adenylated species (AppDNA) that migrated 1-nt slower than the
input 18-mer during polyacrylamide gel electrophoresis (Fig. 7C).
The ability of MPA to inhibit this second step of the ligase reaction
was investigated by pre-incubating the enzyme with ATP to ensure
formation of the covalent enzyme-AMP complex, and by
incubating the complex in the presence of the ligation substrate
that contains a 1-nt gap between the reactive 39-OH and 59-
phosphate strands. Using this strategy, it was determined that a
concentration of 600 mM of MPA is sufficient to inhibit 50% of the
second step of the ligation reaction (Fig. 7C). Taken together, these
results indicate that MPA inhibits the ligation reaction mainly
through inhibition of the second step of the reaction, i.e. the
catalytic transfer of the AMP moiety onto the 59-phosphate
terminus of the nicked DNA substrate.
Inhibition of RNA cap formation in cells
The effect of MPA on the capping of mRNAs was then assessed
in vivo. A primer extension assay was used to monitor the effect of
MPA on the formation of the RNA cap structure in S. cerevisiae.
Previous studies have shown that during cDNA synthesis by
reverse transcriptase, the presence of a cap structure results in the
synthesis of products that harbor an extra 39 nucleotide [40,59].
We therefore performed primer extension assays with a 59 P
32-
labeled 18-mer oligonucleotide complementary to the 59 region of
the SSA1 mRNA. The oligonucleotide was annealed to total
mRNAs extracted from cells that were grown in the presence or
absence of 500 mg/ml MPA for 3 h, and extended with reverse
transcriptase. Our results indicate that cDNA products with
apparent chain lengths of 71 and 72 nucleotides, corresponding to
uncapped and capped mRNAs, were synthesized using mRNAs
extracted from untreated cells (Fig. 8). However, treatment with
MPA resulted in a marked reduction of the 72 nucleotides species,
indicating that cap formation was inhibited in the presence of
MPA. Quantitative analysis indicate that cap formation was
reduced by 50% in the presence of 500 mg/ml MPA (Fig. 8). We
conclude that the addition of MPA to S. cerevisiae cells leads to an
inhibiton of RNA cap synthesis.
Conclusion
The current study provides the first biochemical evidence that
MPA can directly interact with an RNA guanylyltransferase and
inhibit its activity. We demonstrated that MPA inhibits the RNA
guanylyltransferase reaction by preventing the catalytic transfer of
the GMP moiety onto an acceptor RNA. Moreover, our RNA
binding studies demonstrated that the binding of the enzyme-
GMP intermediate to RNA is inhibited in the presence of MPA.
As such, MPA represents a novel type of inhibitor against RNA
guanylyltransferases that inhibits the second step of the catalytic
reaction. Several inhibitors of the RNA guanylyltransferase
activity have previously been identified [60]. However, these
inhibitors all target the formation of the enzyme-GMP complex.
For instance, foscarnet inhibits the formation of the enzyme-GMP
intermediate on account of its analogous nature to pyrophosphate
(PPi), a product of the RNA guanylyltransferase reaction [24].
Ribavirin, a broad-spectrum nucleoside analogue used as an
antiviral for severe respiratory syncytial virus, Hepatitis C and
other viral infections, is another example of an RNA guanylyl-
transferase inhibitor that prevents the formation of the enzyme-
GMP intermediate [25]. Non-nucleoside competitive inhibitors
have also been generated against the RNA guanylyltransferase of
respiratory syncitial virus [61]. MPA, with its ability to inhibit the
second step of the RNA guanylyltransferase reaction, has the
potential to serve as a template for the development of more
potent inhibitors. In fact, a number of MPA derivatives have been
developed in recent years [62,63]. Analysis of the interaction
between these derivatives and RNA guanylyltransferases could
shed light on the chemistry of the RNA capping reaction and lead
to the development of more efficient anti-proliferative/anti-
microbial drugs.
What is the biological relevance of the present finding? MPA
has been shown to cause a reduction of the cellular GTP pools
through the inhibition of IMPDH which is required for the de novo
biosynthesis of GTP [41,42]. A decrease in GTP concentrations
could potentially have a negative effect on the capping of mRNAs.
Evidence for this mechanism comes from studies performed with
both the Sindbis virus and the Borna disease virus that showed
that the viruses cannot replicate in cultured cells treated with
Figure 8. MPA inhibits RNA capping in S. cerevisiae cells. Primer
extension assays were performed with a 59 P
32-labeled 18-mer
oligonucleotide complementary to the 59 region of the SSA1 mRNA.
The oligonucleotide was annealed to total mRNAs extracted from cells
that were grown in the absence (2MPA) or presence (+MPA) of 500 mg/
ml MPA for 3 h, and extended with reverse transcriptase. The primer
extension reactions were analyzed by electrophoresis through a 8%
polyacrylamide gel containing 7 M urea in TBE and visualized by
autoradiography. Control P
32-labeled RNA transcripts of 74 (C1) and 73
(C2) nucleotides were run in parallel. The positions and sizes (in nt) of
the size markers are indicated on the left.
doi:10.1371/journal.pone.0024806.g008
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capping of viral RNAs [48,64,65]. However, mounting evidence
indicates that the antiproliferative/antimicrobial effect of MPA is
not mediated entirely through the reduction of the intracellular
GTP pool. For instance, MPA is not always a potent viral inhibitor
[66]. The second mechanism by which MPA could inhibit the
capping of mRNAs is by directly inhibiting the activity of GTases,
as we demonstrated in the current study. Moreover, we do not
exclude the possibility that MPA may have an increased frequency
of utilization in vivo when the levels of GTP are lowered through
the inhibition of IMPDH. In the present study, we demonstrated
that MPA can inhibit RNA guanylyltransferases and ligases. MPA
therefore appears as a pleiotropic agent that may function through
multiple targets (IMPDH, RNA guanylyltransferase, ligases), as
recently suggested through proteomic analysis [67]. As such, MPA
shares many properties with ribavirin. Both compounds lead to a
reduction of the de novo synthesis of GTP through IMPDH
inhibition, and both molecules can inhibit RNA capping, albeit
through different mechanisms of inhibition.
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